Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 17, 2018Three Posters Highlighting Updated Data from the STOMP Arms Evaluating Selinexor and Dexamethasone in Combination with Velcade®, Pomalyst®, or Darzalex® in Relapsed or Refractory Multiple Myeloma
NEWTON, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three posters highlighting clinical data...
-
May 16, 2018A Total of Four Posters Highlighting Selinexor Data in Hematologic and Solid Tumor Malignancies Will Be Presented at the Meeting
NEWTON, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that four posters will be presented at the upcoming
-
May 10, 2018-- Oral selinexor Achieves 25.4% Overall Response Rate and Median Duration of Response of 4.4 Months in Patients with Penta-Refractory Myeloma --
NEWTON, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2018 and...
-
May 7, 2018
NEWTON, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the closing of its previously announced...
-
May 4, 2018
NEWTON, Mass., May 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
May 3, 2018-- Conference Call Scheduled for Thursday, May 10, 2018 at 8:30 a.m. ET --
NEWTON, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2018...
-
May 2, 2018
NEWTON, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of its previously announced...
-
Apr 30, 2018- Oral Selinexor Achieves 25.4% Overall Response Rate and Median Duration of Response of 4.4 Months in Patients with Penta-Refractory Myeloma -
NEWTON, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from the Phase 2b...
-
Apr 10, 2018
NEWTON, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration...
-
Apr 2, 2018
NEWTON, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...